Michael Torres focuses on innovation at the intersection of technology, medicine, and healthcare delivery. His coverage spans medical devices, digital health, diagnostics, and emerging care models. At The Catalyst Brief, Michael evaluates how new tools translate from concept to real-world impact, considering clinical evidence, adoption challenges, and broader industry implications.
129 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
AI in Drug DiscoveryUnitedHealthcare’s introduction of Avery marks a step forward in integrating artificial intelligence to enhance patient experience. Avery combines advanced AI capabilities with live support to streamline healthcare management for users.
Michael TorresMar 28, 2026
Regulatory & PolicyThe U.S. Food and Drug Administration has presented its current focal points to legislators, underscoring critical food safety issues and regulatory advances aimed at protecting public health. Key initiatives include enhanced oversight of infant formula, modernized labeling requirements, and stronger measures targeting processed food classifications.
Michael TorresMar 27, 2026
Regulatory & PolicyDenali Therapeutics’ recent FDA nod for Avlayah marks a pivotal moment in the treatment landscape of Hunter syndrome, a rare genetic disorder characterized by complex neurologic challenges. This approval underscores the FDA’s evolving approach to rare diseases and neuroscience-related conditions, offering new hope for patients and informing future drug development.
Michael TorresMar 26, 2026
Healthcare InvestmentRachel Springate of Muse Capital explains why pure DTC approaches rarely succeed in healthcare. Companies that start with patient needs and integrate clinical data and payers show a promising new path for healthcare startups.
Michael TorresMar 24, 2026
AI in Drug DiscoveryUtah’s innovative pilot program using an AI-powered system by Doctronic aims to streamline routine prescription refills to reduce delays and improve medication adherence. However, recent reports indicating vulnerabilities in the AI chatbot used reveal the broader complexities and risks that come with deploying AI systems in healthcare environments. This case study exemplifies the delicate balance between technological advancement and ensuring patient safety.
Michael TorresMar 22, 2026
Regulatory & PolicyThe U.S. Department of Health and Human Services (HHS) is placing increasing emphasis on reducing the reliance on animal testing within pharmaceutical research and development. The FDA and NIH are coordinating new strategies and funding mechanisms designed to promote innovative testing methods that could replace traditional animal-based experiments.
Michael TorresMar 18, 2026
Biopharmaceutical IndustryJohnson & Johnson continues to dominate the pharmaceutical industry by revenue, underscoring its robust portfolio and market presence. Meanwhile, Eli Lilly's recent surge as the leader in obesity treatment highlights shifting dynamics in pharma sectors, attracting substantial investor attention.
Michael TorresMar 18, 2026
Regulatory & PolicyRecent developments in the Epic-Health Gorilla lawsuit reveal serious concerns about data privacy in healthcare interoperability networks. GuardDog Telehealth's admission marks a critical juncture, raising questions about the safeguards in place to protect patient information as providers and tech firms navigate complex data-sharing ecosystems.
Michael TorresMar 17, 2026
Biopharmaceutical IndustryThe rare disease market is poised for remarkable expansion driven primarily by innovative small molecule drugs. Insights from Evaluate underscore the increasing value and potential of these therapies in addressing orphan diseases, shaping the future biopharma landscape.
Michael TorresMar 13, 2026
AI in Drug DiscoveryAmid a wave of technological advances, Microsoft has entered the healthcare AI chatbot space with Copilot Health. By aggregating diverse health data sources, the platform is positioned to support users with personalized medical insights, reflecting the expanding role of artificial intelligence in healthcare delivery.
Michael TorresMar 13, 2026
AI in Drug DiscoveryIn an ambitious move to transform the scientific landscape, Radial aims to dismantle traditional barriers in research methodologies by leveraging AI technologies. Backed by substantial funding, this initiative seeks to usher in an era of accelerated discovery and enhanced reproducibility in science.
Michael TorresMar 11, 2026
Medical TechnologyThe collaboration between Verily and Samsung represents a significant advancement in the integration of wearable health technology into the clinical trial landscape. Their joint effort focuses on utilizing Galaxy smartwatch data to enable remote patient monitoring and data analysis, potentially transforming the way pharmaceutical companies conduct studies and interpret trial results.
Michael TorresMar 10, 2026